Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18880346 | RECOMBINANT ORGANISM AND METHOD | December 2024 | February 2026 | Allow | 13 | 2 | 0 | No | No |
| 18879111 | MODIFIED MICROORGANISM OF GENUS CORYNEBACTERIUM PRODUCING L-GLUTAMIC ACID AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING SAME | December 2024 | January 2026 | Allow | 13 | 2 | 0 | No | No |
| 18957929 | NOVEL CAS EFFECTOR PROTEINS, GENE EDITING SYSTEMS, AND USES THEREOF | November 2024 | October 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18631568 | DNA MODIFYING ENZYMES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | April 2024 | November 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18628400 | DNA MODIFYING ENZYMES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | April 2024 | October 2025 | Abandon | 18 | 2 | 0 | No | No |
| 18627839 | DNA MODIFYING ENZYMES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | April 2024 | August 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18623704 | NUCLEIC ACID MOLECULES ENCODING DNA MODIFYING ENZYMES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND COMPOSITIONS COMPRISING THE SAME | April 2024 | August 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18293690 | VISCOUS POLYHYDROXYALKANOATE, PREPARATION THEREOF, AND USE THEREOF | January 2024 | November 2025 | Allow | 21 | 2 | 1 | Yes | No |
| 18415827 | L-ARGININE-GLYCINE AMIDINOTRANSFERASE AND USE THEREOF IN THE PRODUCTION OF GUANIDINOACETIC ACID | January 2024 | September 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18497106 | ENGINEERED DNASE ENZYMES FOR THROMBOSIS THERAPY | October 2023 | October 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18487157 | NOVEL METALLOPROTEASES | October 2023 | February 2026 | Abandon | 28 | 1 | 1 | No | No |
| 18286832 | METHOD FOR INCREASING PRODUCTIVITY OF 2'-FUCOSYLLACTOSE THROUGH CHANGES IN CULTURE MEDIUM COMPOSITION AND CULTURING | October 2023 | November 2025 | Abandon | 25 | 2 | 0 | Yes | Yes |
| 18479758 | COMPOSITIONS, SYSTEMS, AND METHODS FOR EPIGENETIC REGULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) GENE EXPRESSION | October 2023 | July 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18472881 | RATIONALLY-DESIGNED MEGANUCLEASES WITH ALTERED SEQUENCE SPECIFICITY AND DNA-BINDING AFFINITY | September 2023 | June 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18468813 | GENETICALLY ENGINEERED STRAIN OF ZYMOMONAS MOBILIS AND USES THEREOF | September 2023 | April 2025 | Abandon | 18 | 3 | 1 | No | No |
| 18465727 | OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | September 2023 | June 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18461941 | NUCLEIC ACIDS FOR NUCLEASE-MEDIATED GENOME EDITING | September 2023 | November 2025 | Allow | 26 | 2 | 0 | No | No |
| 18279519 | NOVEL CITRATE SYNTHASE VARIANT AND METHOD FOR PRODUCING O-ACETYL-L-HOMOSERINE OR L-METHIONINE USING SAME | August 2023 | February 2026 | Allow | 29 | 1 | 0 | Yes | No |
| 18360312 | POLYNUCLEOTIDES ENCODING ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR RECOGNITION SEQUENCES IN THE DYSTROPHIN GENE | July 2023 | February 2024 | Allow | 7 | 1 | 0 | No | No |
| 18360517 | POLYNUCLEOTIDES ENCODING ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR RECOGNITION SEQUENCES IN THE DYSTROPHIN GENE | July 2023 | January 2024 | Allow | 6 | 1 | 0 | No | No |
| 18355170 | TEMPERATURE-SENSITIVE CAS9 PROTEIN | July 2023 | February 2026 | Abandon | 31 | 2 | 1 | No | Yes |
| 18352414 | COMBINATION TREATMENT BY ADMINISTERING A RECOMBINANT APYRASE PROTEIN IN CONJUNCTION WITH A P2Y12 INHIBITOR | July 2023 | March 2026 | Allow | 32 | 1 | 1 | No | No |
| 18352037 | FUSION MOLECULES OF RATIONALLY-DESIGNED DNA-BINDING PROTEINS AND EFFECTOR DOMAINS | July 2023 | July 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18341669 | Compositions and Methods for Producing High Secreted Yields of Recombinant Proteins | June 2023 | February 2025 | Allow | 19 | 1 | 1 | No | No |
| 18320367 | YEAST CELLS HAVING DISRUPTED PATHWAY FROM DIHYDROXYACETONE PHOSPHATE TO GLYCEROL | May 2023 | September 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18144503 | METHOD FOR PRODUCTION OF MOTH PHEROMONES IN YEAST | May 2023 | October 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18171272 | POLYNUCLEOTIDES ENCODING ENGINEERED IMINE REDUCTASES | February 2023 | May 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18165191 | METHOD FOR PRODUCING POLYISOPRENOID BY REACTION CATALYZED BY MUTANT CIS-PRENYLTRANSFERASE (CPT) FAMILY PROTEIN, AND METHOD FOR PRODUCING RUBBER PRODUCT | February 2023 | January 2026 | Allow | 36 | 2 | 1 | Yes | No |
| 18018561 | NITRILASE MUTANT AND USE THEREOF IN CATALYTIC SYNTHESIS OF 2-CHLORONICOTINIC ACID | January 2023 | September 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18100801 | FUNCTIONALISED POLSULPHIDE SYNTHESIS METHOD | January 2023 | March 2026 | Abandon | 38 | 3 | 1 | No | No |
| 18006251 | SEQUENCE SPECIFIC DEGRADATION OF SINGLE-STRANDED POLYNUCLEOTIDES WITH CARD1 NUCLEASE | January 2023 | March 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 18154231 | NON-STANDARD AMINO ACID CONTAINING COMPOSITIONS AND USES THEREOF | January 2023 | May 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18153822 | METHODS AND COMPOSITIONS FOR ENHANCED ETHANOL PRODUCTION IN YEAST CELLS | January 2023 | September 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18067421 | PRODUCTION OF GLYCOLATE FROM ETHYLENE GLYCOL AND RELATED MICROBIAL ENGINEERING | December 2022 | December 2025 | Abandon | 36 | 3 | 1 | No | No |
| 18057480 | CONJUGATE COMPRISING AN ACTIVE MMP-9-BINDING PEPTIDE | November 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 18054791 | METHODS OF USE FOR AN NADPH-REGENERATION SYSTEM BASED ON A MONOMERIC ISOCITRATE DEHYDROGENASE | November 2022 | April 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18054142 | METHOD FOR PURIFYING INDOLE-3-LACTIC ACID FROM LACTOBACILLUS PLANTARUM FERMENTATION SUPERNATANT | November 2022 | October 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 18053328 | EFFECTOR PROTEINS AND METHODS OF USE | November 2022 | December 2024 | Abandon | 26 | 3 | 1 | Yes | No |
| 18051024 | Method for producing 2-keto-3-deoxygluconate from 2-(acetylamino)-2-deoxy-D-gluconic acid by two enzymes | October 2022 | December 2023 | Allow | 13 | 1 | 0 | Yes | No |
| 17997037 | Parent Phytase Variant | October 2022 | October 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17919588 | GENOME EDITING USING CAS9 OR CAS9 VARIANT | October 2022 | January 2026 | Abandon | 39 | 1 | 1 | No | No |
| 17947048 | PRODUCTION OF CHEMICALS FROM RENEWABLE SOURCES | September 2022 | April 2023 | Allow | 7 | 1 | 1 | No | No |
| 17932420 | KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES | September 2022 | July 2024 | Allow | 22 | 2 | 1 | Yes | No |
| 17931896 | POLYNUCLEOTIDES ENCODING ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR RECOGNITION SEQUENCES IN THE DYSTROPHIN GENE | September 2022 | April 2023 | Allow | 7 | 1 | 1 | Yes | No |
| 17930595 | COMPOSITIONS COMPRISING A CRISPR NUCLEASE AND USES THEREOF | September 2022 | February 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 17929162 | DNA MODIFYING ENZYMES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | September 2022 | March 2024 | Allow | 18 | 3 | 1 | Yes | No |
| 17822733 | PROCESS FOR PRODUCING A GLUCURONIDE AND GENETICALLY MODIFIED MICROORGANISMS USEFUL IN THIS PROCESS | August 2022 | March 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 17888027 | DUAL GUIDE CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE | August 2022 | March 2026 | Allow | 43 | 2 | 1 | Yes | No |
| 17885876 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING STATHMIN 2 (STMN2) AND USES THEREOF | August 2022 | May 2025 | Abandon | 33 | 1 | 2 | No | No |
| 17879030 | AUTOMATIC DISHWASHING DETERGENT COMPOSITION | August 2022 | October 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17873485 | METHODS USING NOVEL CPF1 MUTATIONS THAT ENHANCE THE DNA CLEAVAGE ACTIVITY OF ACIDAMINOCOCCUS SP. CPF1 | July 2022 | March 2025 | Allow | 31 | 3 | 0 | Yes | No |
| 17812259 | Carbohydrate Binding Module Variants And Hybrid Polypeptides Comprising Same | July 2022 | December 2025 | Allow | 41 | 6 | 1 | No | No |
| 17716624 | LIPASE VARIANTS AND THE USE THEREOF | July 2022 | July 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17851880 | DNA MODIFYING ENZYMES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | June 2022 | April 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17849581 | POLYNUCLEOTIDE ENCODING MODIFIED CAS9 PROTEIN | June 2022 | March 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17847313 | Compositions And Methods For Production Of Salidroside, Icariside D2, And Precursors Of Salidroside And Icariside D2 | June 2022 | April 2025 | Allow | 33 | 2 | 1 | No | No |
| 17841082 | BASE EDITING ENZYMES | June 2022 | February 2025 | Allow | 32 | 4 | 1 | Yes | No |
| 17833763 | GLUCOSE/GALACTOSE BIOSENSORS AND METHODS OF USING SAME | June 2022 | December 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17833492 | BACTERIAL CONSORTIA FOR ENHANCING CONVERSION OF ORGANIC SOIL PHOSPHOROUS TO ORTHOPHOSPHATE AND METHODS FOR MAKING AND USING SAME | June 2022 | May 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17833788 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF ARMODAFINIL | June 2022 | December 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17831011 | ADIPATE (ESTER OR THIOESTER) SYNTHESIS | June 2022 | February 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17830650 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | June 2022 | November 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17779561 | HOST CELLS AND THEIR USE FOR PRODUCING RIBITOL AND FURTHER MONOSACCHARIDES | May 2022 | September 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17746851 | EFFECTOR PROTEINS AND METHODS OF USE | May 2022 | June 2023 | Allow | 13 | 1 | 1 | Yes | No |
| 17745630 | GENETICALLY ENGINEERED CELLS | May 2022 | September 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17776363 | VARIANT POLYPEPTIDES HAVING ENHANCED ACTIVITY OF 3-METHYL-2-OXOBUTANOATE HYDROXYMETHYLTRANSFERASE AND MICROORGANISMS FOR PRODUCING PANTOTHENIC OR PANTOIC ACID | May 2022 | March 2026 | Allow | 46 | 1 | 1 | Yes | No |
| 17734169 | CREATININE DEIMINASE AND USES THEREOF | May 2022 | June 2023 | Abandon | 14 | 1 | 1 | No | No |
| 17768635 | MAD7 NUCLEASE IN PLANTS AND EXPANDING ITS PAM RECOGNITION CAPABILITY | April 2022 | April 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17713015 | CARBON NEGATIVE PRODUCTION OF DIACIDS AND OTHER BIOCHEMICALS USING CELL FREE BIOCATALYSIS | April 2022 | September 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17763384 | FUSION PROTEINS FOR DNA BASE EDITING | March 2022 | February 2026 | Allow | 47 | 2 | 2 | No | No |
| 17695219 | COMPOSITIONS AND METHODS FOR PRODUCING HIGH SECRETED YIELDS OF RECOMBINANT PROTEINS | March 2022 | March 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17589594 | NUCLEIC ACIDS ENCODING ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE | January 2022 | November 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17631429 | MODIFIED HOST CELLS FOR HIGH EFFICIENCY PRODUCTION OF VANILLIN | January 2022 | July 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17585119 | GLYCEROL 3-PHOSPHATE OXIDASE MUTANTS, COMPOSITIONS, DEVICES, KITS AND USES THEREOF | January 2022 | June 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17572018 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof | January 2022 | January 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17564601 | MUTANT STRAIN HAVING POLYHYDROXYBUTYRATE PRODUCTION ABILITY AND METHOD FOR PRODUCING POLYHYDROXYBUTYRATE USING THE STRAIN | December 2021 | February 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17563127 | CELLS COMPRISING MOGROSIDE PATHWAY ENZYMES AND USES THEREOF | December 2021 | April 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17557904 | METHODS FOR PRODUCING AFLIBERCEPT IN CHEMICALLY DEFINED MEDIA HAVING REDUCED AFLIBERCEPT VARIANTS | December 2021 | May 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17555974 | CAS9 FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | December 2021 | March 2024 | Allow | 27 | 3 | 1 | Yes | No |
| 17554465 | CRISPR-CAS COMPLEX | December 2021 | July 2023 | Allow | 19 | 2 | 1 | Yes | No |
| 17549757 | RECOMBINANT MICROORGANISM TRANSFORMED WITH A GLUTARIC ACID TRANSPORTER GENE AND METHOD OF PREPARING GLUTARIC ACID USING SAME | December 2021 | December 2023 | Allow | 24 | 3 | 0 | No | No |
| 17544618 | Preparation of (R)-3-Hydroxybutyric Acid or Its Salts by One-Step Fermentation | December 2021 | May 2023 | Abandon | 17 | 0 | 1 | No | No |
| 17529860 | NON-CANONICAL LIPOPROTEINS WITH PROGRAMMABLE ASSEMBLY AND ARCHITECTURE AND METHOD OF MAKING NON-CANONICAL LIPOPROTEINS | November 2021 | September 2023 | Allow | 22 | 2 | 1 | Yes | No |
| 17605389 | PRODUCTION OF CHEMICALS FROM RENEWABLE SOURCES | October 2021 | November 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17491729 | SPLIT INTEINS, CONJUGATES AND USES THEREOF | October 2021 | April 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17482193 | Recombinant Glycoproteins and Uses Thereof | September 2021 | October 2023 | Abandon | 24 | 1 | 1 | No | No |
| 17479010 | METHODS OF DETECTING A POLYPEPTIDE HAVING ANAPLASTIC LYMPHOMA KINASE ACTIVITY IN KIDNEY CANCER | September 2021 | October 2023 | Abandon | 25 | 1 | 1 | No | No |
| 17479173 | POLYNUCLEOTIDES ENCODING OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | September 2021 | June 2023 | Allow | 21 | 1 | 1 | No | No |
| 17472028 | NUCLEIC ACID ENCODING A MODIFIED HOMOSERINE DEHYDROGENASE | September 2021 | September 2022 | Allow | 12 | 0 | 0 | Yes | No |
| 17405670 | COMBINATION TREATMENT | August 2021 | July 2023 | Abandon | 23 | 1 | 1 | No | No |
| 17387780 | PEPTIDE BARCODES FOR CORRELATING NUCLEIC ACID-GUIDED NUCLEASE OR NICKASE FUSION EDITING AND PROTEIN TRANSLATION IN A POPULATION OF CELLS | July 2021 | March 2022 | Abandon | 8 | 2 | 1 | No | No |
| 17383322 | METHODS FOR PRODUCING AFLIBERCEPT IN CHEMICALLY DEFINED MEDIA HAVING REDUCED AFLIBERCEPT VARIANTS | July 2021 | August 2022 | Allow | 13 | 2 | 1 | Yes | No |
| 17419048 | A METHOD FOR THE PRODUCTION OF GLUFOSINATE-AMMONIUM | June 2021 | February 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17357196 | ACETOHYDROXY ACID SYNTHASE VARIANT AND A MICROORGANISM COMPRISING THE SAME | June 2021 | February 2022 | Allow | 7 | 1 | 0 | No | No |
| 17353323 | RECOMBINANT ACID-RESISTANT YEAST HAVING IMPROVED LACTIC-ACID-PRODUCING ABILITY | June 2021 | November 2023 | Allow | 29 | 2 | 1 | Yes | No |
| 17414021 | Coryneform Bacterium Transformant and Method for Producing 2-Phenylethanol Using Same | June 2021 | February 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17344442 | METHODS OF USING DNASE1-LIKE 3 IN THERAPY | June 2021 | September 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17332821 | DNase I Variants, Compositions, Methods, and Kits | May 2021 | January 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17323675 | Recombinant Yeast Strains For Pentose Fermentation | May 2021 | June 2024 | Abandon | 37 | 4 | 1 | No | Yes |
| 17294254 | A METHOD FOR PROCESSING BIOMASS DIGESTATE | May 2021 | November 2025 | Abandon | 54 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAMIREZ, DELIA M.
With a 11.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RAMIREZ, DELIA M works in Art Unit 1652 and has examined 1,224 patent applications in our dataset. With an allowance rate of 60.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner RAMIREZ, DELIA M's allowance rate of 60.0% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RAMIREZ, DELIA M receive 1.78 office actions before reaching final disposition. This places the examiner in the 39% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by RAMIREZ, DELIA M is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +52.9% benefit to allowance rate for applications examined by RAMIREZ, DELIA M. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.2% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 56.5% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 64.7% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 9.4% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.